Early prediction of response to chemotherapy in metastatic breast cancer using sequential18F-FDG PET

Journal of Nuclear Medicine

Volumn 46, Issue 7, 2005, Pages 1144-1150

  Schwarz, Joerg Dose ^a   Bader, Michael ^a   Jenicke, Lars ^a   Hemminger, Gabriele ^a   Jänicke, Fritz ^a   Avril, Norbert ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

18F FDG; Breast cancer; Metastases; PET; Prediction of response to therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GLUCOSE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMAGE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CARCINOMA; FEMALE; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 23844481161     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002;29:38-43.
2. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
3. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
4. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorode oxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
5. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
6. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging results of a prospective trial. J Clin Oncol. 2003;21:4604-4610.
7. Wieder H, Brucher BL, Zimmerman F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-909.
8. Rose C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun. 2002;23:613-618.
9. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
10. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 1995;196:167-173.
11. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771-1777.
12. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography initial evaluation. J Clin Oncol. 1993;11:2101-2111.
13. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer a method for early therapy evaluation? J Clin Oncol. 1995;13 1470-1477.
14. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56.
15. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676-1688.
16. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [F-18]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18;1689-1695.
17. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806-1814.
18. Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET quantitative image analysis. J Nucl Med. 1997;38:1186-1191.
19. Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol. 2002;9: 913-921.
20. 18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer. 2000; 1:156-161.
21. Mincey BA, Perez EA. Advances in screening, diagnosis, and treatment of breast cancer. Mayo Clin Proc. 2004;79:810-816.